Canadian vaccine maker Medicago's COVID-19 vaccine, approved last month in Canada, is facing limited growth in the near-term after the World Health Organization said it would not review the ...

Medicago truncatula articles from across Nature Portfolio. Atom; RSS Feed; Definition. Medicago trunculata, or barrel clover, is a small annual plant in the legume family (Fabaceae) that serves as ...

Dr. Naresh Aggarwal talks with Jennifer Bain, who volunteered for a study of Medicago's COVID-19 vaccine, in Toronto. More than 24,000 volunteers in six countries participated.

Canadian drug developer Medicago's plant-based COVID-19 vaccine candidate, enhanced by GlaxoSmithKline's booster, was 75.3% effective against the Delta variant of the virus in a late stage study ...

Medicago’s vaccine prevents Covid-19, but the WHO may reject it anyway because the Canadian pharmaceutical company is partially owned by cigarette giant Philip Morris International.

In the crowded race for a coronavirus vaccine, Medicago stands out. The Canadian company's unusual approach relies on growing rows and rows of a tobacco-like crop in a North Carolina greenhouse ...

QUEBEC CITY--(BUSINESS WIRE)--Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase I clinical trials for its plant-derived COVID-19 vaccine candidate yesterday ...

Medicago’s platform can produce both vaccine and antibody candidates against COVID-19 disease. March 12, 2020 07:30 AM Eastern Daylight Time. QUEBEC CITY, Quebec-- ...

A new kind of COVID-19 vaccine could be available as soon as this summer. It's what's known as a protein subunit vaccine.It works somewhat differently from the current crop of vaccines authorized ...

QUEBEC CITY, June 6, 2013 /CNW/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary ...

GlaxoSmithKline Plc and Medicago Inc. said their Covid-19 vaccine candidate spurred protective antibody levels 10 times higher than in patients who have recovered from the disease in interim trial ...